In 236 adults with Ph-positive acute lymphoblastic leukaemia, frontline ponatinib plus blinatumomab gave higher 24-month event-free survival than imatinib plus chemotherapy (86% vs 67%, P<0.001) in a phase 3 trial; overall survival was 90% vs 85%.
RCTn = 236
Chiaretti et al. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL